NT Health Research and Publications Online

Title
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Subject
Stroke
Type of document
Interventional/Clinical trials research
Entity Type
Project
Abstract
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Link
link

Files:

NameSizeformatDescriptionLink